GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Telesis Bio Inc.
The stock price of Telesis Bio, a company developing tools for synthetic biology, reflects demand for its technologies from R&D labs. Its price trajectory depends on sales of equipment and consumables, as well as overall funding in the biotech sector.
Share prices of companies in the market segment - Dna
Telesis Bio provides automated DNA and RNA synthesis platforms, accelerating research in synthetic biology, gene therapy, and vaccine development. We've categorized it as "DNA" because its technologies are key to genetic engineering. The graph below illustrates the dynamics of this entire cutting-edge sector.
Broad Market Index - GURU.Markets
Telesis Bio is a company that provides a synthetic biology platform, enabling scientists to rapidly create and modify DNA. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Telesis's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
TBIO - Daily change in the company's share price Telesis Bio Inc.
Telesis Bio, Inc.'s daily price change reflects the high volatility inherent in synthetic biology companies. This metric measures its sensitivity to demand for its DNA-creation equipment from research labs.
Daily change in the price of a set of shares in a market segment - Dna
Telesis Bio (formerly Codex DNA) produces automated DNA and mRNA synthesis systems, accelerating biotech research. The genomics equipment market is highly technological and competitive. The graph below shows the average volatility in this sector, allowing one to assess how the market is embracing TBIO's innovations.
Daily change in the price of a broad market stock, index - GURU.Markets
Telesis Bio is a life sciences company producing DNA and RNA synthesis platforms. Its business is a barometer of R&D activity in the pharmaceutical industry. Its stock price is an indicator of innovation activity, which influences the overall market environment.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Telesis Bio Inc.
Telesis Bio, Inc.'s year-to-date performance tells the story of its role in synthetic biology. Its 12-month market cap growth reflects demand for its DNA and RNA synthesis equipment from pharmaceutical and biotech companies. Its valuation is a bet that its automation technology will accelerate the development of new drugs and vaccines.
Annual dynamics of market capitalization of the market segment - Dna
Telesis Bio, Inc. provides DNA and RNA synthesis tools. Its technology accelerates biotech research. The graph illustrates how its key role in this ecosystem, its dependence on R&D budgets, and competition influence its performance in the life sciences sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Telesis Bio, a supplier of synthetic biology tools, is an "infrastructure" bet on biotech. Its performance relative to the market is a barometer of R&D spending in the pharmaceutical industry. The growth of the biotech sector is driving demand for its equipment, allowing it to outpace the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Telesis Bio Inc.
Telesis Bio produces instruments for synthetic biology. Its monthly growth is driven by R&D spending by biotech and pharmaceutical companies. Quarterly sales reports for its equipment and consumables are key indicators.
Monthly dynamics of market capitalization of the market segment - Dna
Telesis Bio, operating under the brand Codex DNA, produces automated systems for synthetic biology. Its devices allow scientists to "print" DNA, accelerating research and drug development. The graph below shows the dynamics of the biotech sector, where such tools are key to innovation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Telesis Bio (formerly Codex DNA) produces tools for synthetic biology, allowing scientists to "print" DNA. This is an innovative industry. The company's shares are driven by news of the implementation of its technology and the growth of biotech R&D, rather than by general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Telesis Bio Inc.
Telesis Bio, a synthetic biology toolmaker, shares weekly reflect the pace of innovation in biotech. Its price movement reflects demand for its DNA assembly equipment from labs developing new drugs and vaccines.
Weekly dynamics of market capitalization of the market segment - Dna
Telesis Bio (formerly Codex DNA) produces synthetic biology tools, including "DNA printers." This chart shows how the market values its breakthrough technology relative to the biotech sector, reflecting investor confidence in its ability to accelerate research and development.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Telesis Bio is a biotech company whose value depends on the implementation of its technologies. Shares in this sector often move independently of the market. This chart will help you understand: do Telesis Bio shares follow the broader market or are news about its developments creating a completely independent trajectory?
Market capitalization of the company, segment and market as a whole
TBIO - Market capitalization of the company Telesis Bio Inc.
Telesis Bio's market capitalization tells the story of a company that provides tools for automating DNA and RNA synthesis for biotech research. Its chart reveals both its vast potential and the difficulty of commercializing its equipment in this market. Its performance reflects the market's assessment of its technology and its ability to compete.
TBIO - Share of the company's market capitalization Telesis Bio Inc. within the market segment - Dna
Telesis Bio (formerly Codex DNA) produces tools for synthetic biology, including DNA printers. Its share of its segment's market capitalization reflects its innovative status. The chart below shows how the market perceives the potential of its technologies to accelerate biotech research.
Market capitalization of the market segment - Dna
Telesis Bio (formerly Codex DNA) produces automated gene synthesis systems. The graph below shows the market capitalization of the life sciences sector. Its growth reflects the revolution in synthetic biology, where Telesis technology allows researchers to create DNA for their experiments faster and easier.
Market capitalization of all companies included in a broad market index - GURU.Markets
Telesis Bio is a company creating tools for synthetic biology, specifically for automated DNA synthesis. Its market cap is a bet that gene engineering will become as accessible as programming. Its momentum is the pulse of the biotech revolution at its most fundamental level.
Book value capitalization of the company, segment and market as a whole
TBIO - Book value capitalization of the company Telesis Bio Inc.
Telesis Bio's foundation is its capital and production capacity for automated DNA and mRNA synthesis systems. This is real, technological capital that accelerates research in synthetic biology. How has this "instrumental" biotech asset evolved? The chart below shows its dynamics.
TBIO - Share of the company's book capitalization Telesis Bio Inc. within the market segment - Dna
Telesis Bio produces DNA and RNA synthesis equipment. The chart shows the proportion of its R&D and manufacturing assets, reflecting the physical scale behind the creation of tools for modern synthetic biology.
Market segment balance sheet capitalization - Dna
Telesis Bio, a manufacturer of DNA synthesis equipment, is a capital-intensive business. It requires cleanroom facilities to build its complex machines. The BCap_Seg chart for the medical equipment sector shows that success in this sector requires a robust manufacturing base.
Book value of all companies included in the broad market index - GURU.Markets
Telesis Bio's capital is its technology and manufactured devices (BioXp) for automated gene and mRNA synthesis, which accelerates the development of vaccines and drugs. Its assets are its patents and manufacturing capabilities. The chart shows the material wealth of this "biological printer" provider.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Telesis Bio Inc.
Telesis Bio produces tools for synthetic biology. Its balance sheet consists of its equipment and patents. Its market capitalization is a bet that its technologies will accelerate research in pharmaceuticals and biotech. The chart shows how the market values a company that created shovels during the biotech gold rush.
Market to book capitalization ratio in a market segment - Dna
Telesis Bio provides automated systems and reagents for synthetic biology that enable scientists to rapidly create and modify DNA. Its high score on the chart reflects the value of its technologies in accelerating biotech research.
Market to book capitalization ratio for the market as a whole
Telesis Bio, Inc. produces equipment and reagents for synthetic biology. It's a science-intensive business where value is created through technology and patents. This chart shows the premium investors are willing to pay for companies providing the tools for the biotech revolution.
Debts of the company, segment and market as a whole
TBIO - Company debts Telesis Bio Inc.
Telesis Bio, a company that provides gene synthesis and laboratory automation tools, uses capital for R&D and the commercialization of its platform. This chart shows how the synthetic biology company funds its innovations, aiming to speed up and reduce the cost of genetic engineering for its clients.
Market segment debts - Dna
Telesis Bio (formerly Codex DNA) produces automated systems for synthetic biology, enabling scientists to "print" DNA. This timeline illustrates how the advanced laboratory equipment company is funding its R&D and commercialization efforts to make its breakthrough technology an industry standard.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Telesis Bio Inc.
Telesis Bio (formerly Codex DNA) produces automated DNA and mRNA synthesis systems, accelerating biotechnology research. This chart shows how the company uses debt to finance the production of its sophisticated equipment, R&D, and marketing. It helps evaluate its financing strategy in this cutting-edge scientific niche.
Market segment debt to market segment book capitalization - Dna
Telesis Bio, formerly known as Codex DNA, produces automated DNA and mRNA synthesis systems, accelerating biotech research. It's a "gene printer." The chart shows debt trends in the sector, providing context for assessing how Telesis Bio finances its capital-intensive innovations.
Debt to book value of all companies in the market
Telesis Bio, Inc. (formerly Codex DNA) develops tools for synthetic biology, which requires investment in R&D and high-tech manufacturing. This chart, showing the overall debt burden in the market, helps assess how this company in the "science tools" sector finances its innovations and the sustainability of its debt strategy.
P/E of the company, segment and market as a whole
P/E - Telesis Bio Inc.
Telesis Bio offers automated gene and mRNA synthesis platforms that accelerate research in synthetic biology. This chart shows how the market is evaluating its tools for scientists. The dynamics reflect the growth of the biotechnology industry and the demand for automation in laboratory processes.
P/E of the market segment - Dna
This chart shows the average P/E for biotech companies. It serves as a backdrop for Telesis Bio, with its DNA synthesis technology. It shows how companies creating tools for scientific breakthroughs are valued on average, providing context for Telesis's valuation, which is betting on its unique technology platform.
P/E of the market as a whole
Telesis Bio is a company that provides synthetic biology tools that help researchers create DNA. Its business depends on R&D in the biotech and pharmaceutical industries. This general sentiment graph influences biotech funding, but for Telesis, the long-term trend in synthetic biology is more important.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Telesis Bio Inc.
This chart from Telesis Bio, Inc., a company that provides DNA and RNA synthesis tools, shows market expectations for future sales of its equipment. It reflects forecasts for the growth of the synthetic biology market and demand for its technologies from pharmaceutical and biotech companies.
%20P%2FE%20Telesis%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Telesis-Bio-Inc.&v=1772513618894 "Chart of the company's future (projected) P/E Telesis Bio Inc.")
Future (projected) P/E of the market segment - Dna
Telesis Bio (formerly Codex DNA) provides synthetic biology tools, including the automated BioXp platform, which allows scientists to create and synthesize DNA and RNA. This chart shows forecasts for the life sciences sector. This helps assess how the market perceives Telesis Bio's role in accelerating research in genetic engineering and vaccine development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513618918 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Telesis Bio, Inc. (formerly Codex DNA) provides tools for synthetic biology, including DNA printers. The company operates at the cutting edge of science. Its valuation is a bet on the growth of the bioeconomy. This chart shows the market's willingness to invest in companies building the infrastructure for the biotech revolution.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513618936 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Telesis Bio Inc.
Telesis Bio, Inc. (formerly Codex DNA) produces automated systems for DNA and mRNA synthesis. The company's revenue depends on sales of these instruments and consumables to laboratories. This graph illustrates how automation in synthetic biology is becoming a commercial reality, but requires significant investment.
Profit of companies in the market segment - Dna
Telesis Bio, operating under the Codex DNA brand, provides synthetic biology tools, including automated DNA assembly systems. This sector profitability chart shows the growing demand for genetic engineering tools. Their technologies accelerate research in pharmaceuticals, agriculture, and other fields that utilize DNA programming.
Overall market profit
Telesis Bio, Inc. provides a DNA and mRNA synthesis platform that allows researchers to quickly create genetic material for their experiments. The company is a provider of tools for the biotech revolution. Demand for its products depends on the volume of R&D in life sciences, which increases during periods of general economic growth, as shown in this graph.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Telesis Bio Inc.
Telesis Bio, operating under the brand Codex DNA, produces automated systems for synthetic biology that allow scientists to quickly "print" DNA. This chart reflects analysts' forecasts for the synthetic biology market growth and the company's equipment and consumables sales to research laboratories.
%20profit%20of%20the%20company%20Telesis%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Telesis-Bio-Inc.&v=1772513619025 "Graph of future (projected) profit of the company Telesis Bio Inc.")
Future (predicted) profit of companies in the market segment - Dna
Telesis Bio (formerly Codex DNA) provides automated synthetic biology systems that enable researchers to rapidly create and modify DNA. The company's growth depends on the development of the synthetic biology market. This biotech chart reflects expected growth in investment in tools that accelerate scientific research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513619074 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Telesis Bio develops DNA and RNA synthesis technologies. Its clients are biotech and pharmaceutical companies. This graph, reflecting revenue expectations, influences the amount of funding these companies allocate to research and development, which directly determines demand for Telesis Bio's instruments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513619121 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Telesis Bio Inc.
Telesis Bio (formerly Codex DNA) provides automated systems for gene and mRNA synthesis. The chart shows a high valuation per dollar of its revenue, reflecting investors' belief that its technology will accelerate research in synthetic biology, vaccine development, and personalized medicine.
P/S market segment - Dna
Telesis Bio, Inc. provides automated DNA and mRNA synthesis systems that accelerate synthetic biology research. The company's revenue is derived from sales of these instruments and consumables. This chart, which reflects the average valuation in the sector, helps understand how investors value Telesis' technology, an essential tool for biotech.
P/S of the market as a whole
Telesis Bio (formerly Codex DNA) provides automated gene and mRNA synthesis systems that accelerate biotechnology research. This chart, showing average market revenue estimates, helps understand the premium investors are willing to pay for technologies that serve as "tools" for creating new drugs and vaccines.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Telesis Bio Inc.
Telesis Bio (formerly Codex DNA) produces automated systems for DNA and mRNA synthesis. Its "BioXp" technology allows scientists to rapidly create genetic constructs in their labs. This chart reflects investor expectations for the future growth of the synthetic biology market and the demand for genetic engineering tools.
%20P%2FS%20Telesis%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Telesis-Bio-Inc.&v=1772513619219 "The graph of the company's future (projected) P/S Telesis Bio Inc.")
Future (projected) P/S of the market segment - Dna
Telesis Bio, Inc., formerly known as Codex DNA, provides automated solutions for synthetic biology, including tools for creating and modifying DNA and RNA. This chart shows the average estimated future sales in the life sciences sector. It helps understand how the market views Telesis Bio's role in accelerating biotech research.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513619248 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Telesis Bio, Inc. provides automated DNA and mRNA synthesis platforms that accelerate research in synthetic biology. This chart shows the market's collective revenue expectations. The company's technologies are an essential tool for scientists working on the development of new drugs, vaccines, and biotech products.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513619270 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Telesis Bio Inc.
This chart shows sales of Telesis Bio, a company that provides synthetic biology tools, including automated DNA assembly systems. Revenue is generated from sales of these instruments and their consumables. The trend reflects demand for genetic engineering technologies in the pharmaceutical and biotech industries.
Sales of companies in the market segment - Dna
Telesis Bio offers a platform for automated gene and mRNA synthesis, enabling researchers to quickly create and test genetic constructs. This graph illustrates the growth of the synthetic biology market. The company's technologies significantly accelerate research in biotechnology and pharmaceuticals, serving as a key enabler for innovation.
Overall market sales
Telesis Bio provides synthetic biology tools, including DNA synthesizers. Demand for its equipment comes from research labs and biotech companies. This total revenue chart reflects the state of the economy, which impacts research and development budgets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Telesis Bio Inc.
Telesis Bio (formerly Codex DNA) produces instruments and reagents for automated gene synthesis, accelerating research in synthetic biology. Future revenues depend on R&D budgets in biotech and pharmaceuticals. The chart shows the growth forecast for this cutting-edge scientific market.
%20sales%20of%20the%20company%20Telesis%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Telesis-Bio-Inc.&v=1772513619322 "Schedule of future (projected) sales of the company Telesis Bio Inc.")
Future (projected) sales of companies in the market segment - Dna
Telesis Bio, operating under the brand Codex DNA, produces automated systems for gene and DNA synthesis. Its tools enable scientists to quickly "write" genetic code for synthetic biology research. This graph shows the forecast for the entire DNA technology market, where Telesis Bio provides key tools for innovation.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513619325 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Telesis Bio, formerly Codex DNA, provides synthetic biology tools, including automated DNA and mRNA assembly systems. Demand for their products depends on biotech R&D funding. This graph, reflecting the investment climate in the life sciences, is an indicator of how actively labs will purchase advanced equipment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513619340 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Telesis Bio Inc.
Telesis Bio (formerly Codex DNA) produces automated DNA and mRNA synthesis systems that accelerate biotechnology research. The company's profitability depends on sales of this sophisticated equipment and consumables. This chart illustrates how the company, by providing a "gene factory" for scientists, strives to turn this cutting-edge technology into a profitable business.
Market segment marginality - Dna
Telesis Bio provides automated systems for the synthesis and assembly of genes and genomes, accelerating research in synthetic biology. Profitability depends on sales of their high-tech instruments and consumables. This chart shows operating results. A comparison with the sector highlights their role as a supplier of key biotechnology tools.
Market marginality as a whole
Telesis Bio (formerly Codex DNA) produces automated gene and DNA synthesis systems. Their equipment (BioXp) allows scientists to quickly create genetic material in the lab. This overall profitability curve is important to them because it impacts the budgets of their clients—biotech and pharmaceutical companies that invest in R&D during periods of growth.
Employees in the company, segment and market as a whole
Number of employees in the company Telesis Bio Inc.
Telesis Bio provides tools for synthetic biology, including automated DNA synthesis systems. Its team consists of engineers and scientists. This chart reflects its investments in the development and commercialization of equipment that accelerates biotech research.
Share of the company's employees Telesis Bio Inc. within the market segment - Dna
Telesis Bio, formerly known as Codex DNA, provides tools for synthetic biology. This chart reflects its role as a technology provider. It shows the size of its team of engineers and scientists who create and sell automated systems that enable other researchers to quickly and accurately "write" and "assemble" DNA and mRNA in their labs.
Number of employees in the market segment - Dna
Telesis Bio, Inc., operating under the brand Codex DNA, provides solutions for automated gene and mRNA synthesis. This chart illustrates employment trends in the synthetic biology sector. The growth in bioengineers and sales professionals reflects growing demand from pharmaceutical and biotech companies for tools that accelerate the development of new drugs and vaccines.
Number of employees in the market as a whole
Telesis Bio develops DNA and RNA synthesis technologies used in biotech research. Demand for its products comes from scientific laboratories and pharmaceutical companies. Overall economic growth, reflected in this graph, supports stable R&D budgets, allowing researchers to invest in cutting-edge genetic engineering tools.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Telesis Bio Inc. (TBIO)
Telesis Bio (formerly Codex DNA) produces equipment and reagents for synthetic biology, including "DNA printers" (BioXp). This is a high-tech "life science tools" sector. The chart shows the market value of their unique technology. The high market capitalization per employee reflects their creation of complex, proprietary instruments (capital) for R&D labs.
%20of%20the%20company%20Telesis%20Bio%20Inc.%20(TBIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Telesis-Bio-Inc.-TBIO&v=1772513619386 "Chart of market capitalization per employee (in thousands of dollars) of the company Telesis Bio Inc. (TBIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Telesis Bio provides automated gene and DNA synthesis systems used in biotech research. It's a company that creates scientific tools. Its value lies in the technology and performance of its equipment. This chart shows how the market values its innovative solutions that accelerate scientific discovery.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513619405 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Telesis Bio offers automated DNA and mRNA synthesis platforms, accelerating research in synthetic biology. The chart shows its valuation in the Life Sciences sector. The high market capitalization per employee reflects the value of their technology, which is a key tool for vaccine and gene therapy developers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513619410 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Telesis Bio Inc. (TBIO)
Telesis Bio (formerly Codex DNA) manufactures and sells instruments (devices and reagents) that automate the process of creating synthetic DNA for laboratories. It's a "razor business" for biotech. This chart shows how successfully their sales team is building an installed base of instruments, which then generates recurring revenue from consumables.
%20Chart%20Telesis%20Bio%20Inc.%20(TBIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Telesis-Bio-Inc.-TBIO&v=1772513619429 "Company Profit Per Employee (in thousands of dollars) Chart Telesis Bio Inc. (TBIO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Telesis Bio (formerly Codex DNA) produces automated systems (BioXp) for DNA and mRNA synthesis in laboratories. This business sells sophisticated scientific equipment and consumables. This metric reflects the company's success in selling its bioprinting systems.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513619453 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Telesis Bio (TBIO) is a biotech company that produces equipment (BioXp) for automated DNA synthesis (like Twist, but hardware). It's a "razor blade business." This chart shows how high their R&D costs (loss per employee) are during the product launch phase.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513619477 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Telesis Bio Inc. (TBIO)
Telesis Bio (formerly Codex DNA) produces automated systems for DNA and mRNA synthesis. This chart shows the demand for its equipment in the biotech industry. The increase in revenue per employee reflects sales of its sophisticated "DNA printers" and related consumables to laboratories worldwide.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Telesis-Bio-Inc.-TBIO&v=1772513619493 "Sales chart per company employee Telesis Bio Inc. (TBIO)")
Sales per employee in the market segment - Dna
Telesis Bio (TBIO) (formerly Codex DNA) sells equipment (BioXp) and reagents that automate the printing of synthetic DNA and mRNA in laboratories. It's a "3D printer" for biologists. This chart shows how much revenue each employee (engineer, salesperson) generates from the sale of these instruments and consumables.
Sales per employee for the market as a whole
Telesis Bio (TBIO) provides synthetic biology solutions, including instruments and reagents for DNA assembly. It's a knowledge-intensive business. This chart shows how efficiently the company sells its equipment (razors) and consumables (blades) to labs and biotech companies, which is key to recurring revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Telesis Bio Inc. (TBIO)
Telesis Bio (formerly Codex DNA) produces instruments and reagents for synthetic biology (DNA synthesis). The bearish sentiment shown by this chart may be related to expectations of reduced funding for biotech (its clients) or the fact that its technology is losing ground to competitors.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Telesis-Bio-Inc.-TBIO&v=1772513619510 "Short Shares Chart for the Company Telesis Bio Inc. (TBIO)")
Shares shorted by market segment - Dna
Telesis Bio (TBIO) is the "shovel supplier" for the biotech revolution. The company produces tools and reagents for synthetic biology, automating DNA and RNA synthesis. This chart shows overall short positions in the biotech sector. If it rises, investors expect a decline in biotech research funding, which will reduce demand for TBIO's equipment.
Shares shorted by the overall market
Telesis Bio produces "tools" (DNA synthesizers) for biotech labs. Their clients are R&D companies. This chart measures general fear. When investors are afraid, they stop funding biotechs. TBIO clients (small biotechs) respond by freezing budgets and cutting spending on new equipment, which hurts Telesis's sales.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Telesis Bio Inc. (TBIO)
Telesis Bio (TBIO), formerly Codex DNA, produces synthetic biology tools, including "DNA printers" (BioXp) that automate gene creation. This cutting-edge technology is used to measure trend strength. This indicator shows when stocks are "overheated" (above 70) on breakout news or "oversold" (below 30) due to slow commercial adoption.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Telesis-Bio-Inc.-TBIO&v=1772513619544 "RSI 14 indicator chart for the company's stock Telesis Bio Inc. (TBIO)")
RSI 14 Market Segment - Dna
Telesis Bio (formerly Codex DNA) is a DNA 2.0 "printer." Their platform (BioXp) is a fully automated desktop DNA and mRNA synthesizer (for R&D). The RSI_14_Seg index for "Dna" (biotech/tools) is fueled by R&D budgets. It shows the "temperature" of the entire industry. It helps us understand: is TBIO's growth a niche or just general hype?
RSI 14 for the overall market
Telesis Bio (TBIO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TBIO (Telesis Bio Inc.)
Telesis Bio (TBIO) produces automated systems (BioXp) that enable labs to "print" DNA (synthesize genes) on demand. This chart shows the analysts' average 12-month forecast, reflecting their view of how quickly R&D labs will adopt this desktop synthetic biology technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TBIO-Telesis-Bio-Inc.&v=1772513619574 "A chart showing analyst consensus forecasts for the expected stock price. TBIO (Telesis Bio Inc.)")
The difference between the consensus estimate and the actual stock price TBIO (Telesis Bio Inc.)
Telesis Bio (TBIO) is a DNA "printer." The company produces devices and software that enable biotech labs to *quickly* (overnight) "print" custom genes for R&D. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their belief in the growth of "synthetic biology."
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TBIO-Telesis-Bio-Inc.&v=1772513619578 "A chart showing the difference between the consensus forecast and the actual stock price. TBIO (Telesis Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Telesis Bio (TBIO) is a "bio-printer." The company produces synthetic DNA and automated "benches" (BioXp) that allow labs to quickly "print" genes for R&D. This chart shows general expectations for the DNA technology sector. It reflects whether experts believe the synthetic biology market will grow.
Analysts' consensus forecast for the overall market share price
Telesis Bio (TBIO) is a DNA "printer." They produce automated "synthesizers" (BioXp) that allow biotech labs to "print" the DNA and RNA sequences they need. This chart shows the overall risk appetite. It reflects the level of confidence analysts have in the R&D budgets of Big Pharma, TBIO's clients.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Telesis Bio Inc.
Telesis Bio (formerly Codex DNA) provides hardware and reagents for synthetic biology, enabling labs to "print" DNA and RNA. It's a "pick-and-shovel" business in biotech, dependent on industry R&D spending. This chart is a composite index assessing the adoption rate of their platform (BioXp), consumable sales, and the overall outlook for the gene synthesis market.
AKIMA Market Segment Index - Dna
Telesis Bio (TBIO) is DNA as a tool. They produce hardware (DNA synthesizers) and software that enable other biotech companies to quickly create and test new gene constructs. This chart compares their DNA service index to the industry average.
The AKIM Index for the overall market
Telesis Bio (formerly Codex DNA) is the creator of an automated desktop DNA and mRNA synthesis system (BioXp). This chart, which reflects the market average, is a risk appetite indicator. It reveals the macro backdrop, which is important for this tech company facing financial challenges.
